Molecular testing prior to first-line therapy in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC): A survey of U.S. medical oncologists.-Reference-Cited by-同舟云学术

Molecular testing prior to first-line therapy in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC): A survey of U.S. medical oncologists.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:8097-8097
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Green Mark R.¹,Willey Joanne¹,Buettner Arden¹,Lankford Maria¹,Neely Doug B.²,Ramalingam Suresh S.³

Affiliation:

1. Xcenda, Palm Harbor, FL

2. Xcenda, Tampa, FL

3. The Winship Cancer Institute of Emory University, Atlanta, GA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.8097

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring non-invasive precision treatment in non-small cell lung cancer patients through deep learning radiomics across imaging features and molecular phenotypes;Biomarker Research;2024-01-25

2. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study;The Lancet Digital Health;2023-07

3. New Actions on Actionable Mutations in Lung Cancers;Cancers;2023-05-26

4. Deep Learning CT Signature Predicts Benefit from Immunotherapy in Metastatic NSCLC Independent of Standard Clinicopathological Markers;SSRN Electronic Journal;2022

5. Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy;Annals of Translational Medicine;2021-12